Last reviewed · How we verify
Ropinirole Prolonged release
Ropinirole Prolonged Release, marketed by Seoul National University Hospital, is an established treatment in its therapeutic class. The key composition patent expires in 2028, providing a period of market exclusivity and potential revenue stability. The primary risk lies in the lack of disclosed primary indication and key trial results, which may limit its competitive positioning against other market players.
At a glance
| Generic name | Ropinirole Prolonged release |
|---|---|
| Also known as | Requip PD® |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD) (PHASE2)
- A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease (PHASE4)
- A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease (PHASE4)
- Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects (PHASE1)
- A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda (PHASE1)
- A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's (PHASE3)
- Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease (PHASE3)
- Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |